Enforcement tracker
Selected FDA warning letters and enforcement actions involving peptide products.
Not legal or medical advice.
This page is for informational purposes only. Always verify the current official source or consult a qualified professional before making compliance, prescribing, purchasing, or clinical decisions. Read full disclaimer.
| Date | Firm | Substances | Action | Source |
|---|---|---|---|---|
| 2024-12-10 | Xcel Research LLC | Retatrutide, sermorelin, semaglutide blends | Warning letter — unapproved new drugs | FDA |
| 2023-06-12 | Warrior Labz SARMS | BPC-157, TB-500 | Warning letter — unapproved new drugs | FDA |
| 2007-08-30 | Melanocorp | Melanotan II | Warning letter — unapproved new drug | FDA |
Sources
- FDA Warning Letter to Melanocorp (Melanotan II)
U.S. Food and Drug Administration · Warning letter
- FDA Warning Letter to Warrior Labz SARMS
U.S. Food and Drug Administration · Warning letter · 655280
- FDA Warning Letter to Xcel Research LLC
U.S. Food and Drug Administration, CDER Office of Compliance · Warning letter · 694608
Last updated: 2025-03-01
Next update: 2025-06-01